Tag: Chance

Categories
Politics

For G.O.P., Infrastructure Invoice Is a Likelihood to Inch Away from Trump

For G.O.P., Infrastructure Bill Is a Chance to Inch Away from Trump

Instead, the response was crickets.

Ms. Collins and Senator Bill Cassidy, Republican of Louisiana, calmly pointed out that Mr. Trump had supported a much larger infrastructure plan in the past but failed to deliver. Mr. Portman, who had personally called Mr. Trump to encourage him to back the legislation, politely suggested that Mr. Trump change tactics and embrace the plan.

When the time came to vote to advance the measure on the Senate floor, the coalition of mostly moderate members found that, contrary to Mr. Trump’s efforts, the number of conservative senators supporting their plan had increased, not decreased — with members of Republican leadership, including Mr. McConnell and Senator Roy Blunt of Missouri, who is also retiring, joining their ranks.

Senator Kevin Cramer, Republican of North Dakota, said some of his constituents were “mad as hell” about his support for the bill — particularly about the idea of doing something that would make President Biden look good. But rather than follow Mr. Trump’s lead, he has made a point of talking up the agreement on conservative talk radio shows.

“I firmly believe that people — the longer they live with it, the more they look at it, the more they hear about it, the more they’ll like it, including conservatives,” Mr. Cramer said.

Several Republican aides said the developments left them feeling that while Mr. Trump’s influence over the Senate was not gone, he was diminished.

Indeed, many Republicans said they were puzzled over the point Mr. Trump was trying to make. The former president had proposed a $1.5 trillion infrastructure package while in office, so his opposition to a leaner bill seemed motivated either by personal pique or a simple desire to see his predecessor and the opposing party fail.

“It’s not really so clear what Trump’s substantive objection is here,” said Philip Wallach, a senior fellow at the conservative American Enterprise Institute. “He’s certainly not saying doing an infrastructure bill is bad; he spent his whole four years talking about how great it would be. So all he’s really saying is, ‘Working with Democrats is bad.’ And for a lot of these senators from closely contested states, they figure their electoral base just doesn’t agree that bipartisanship is bad.”

Categories
Health

Why I Gave My Mosaic Embryo a Likelihood

Why I Gave My Mosaic Embryo a Chance

Five months later, I received a call from a doctor who came to pick up my doctor. She canceled my appointment, claiming she was uncomfortable transferring a mosaic embryo. I was angry and overwhelmed with grief.

“The bigger question that arises with embryo testing is who is running the risk of potentially having a child with potential disabilities,” said Dr. Taylor. “The decision should not be left to the doctors. Patients should be given freedom of choice and appropriate counseling in cases where there are abnormalities that inevitably lead to death. “

Parents I met online described driving or driving their frozen abnormal and mosaic embryos in unwieldy metal tanks to other clinics when their doctors refused to transfer them. Fortunately, my regular doctor came back and made a new appointment for the following month.

My husband and I were lucky. Our beautiful, imperfect embryo is attached to the uterus wall and fascinates us with its wildly beating heart on biweekly ultrasound. With new worries growing every week – that I might have a miscarriage, that the baby might have other abnormalities that embryo tests didn’t detect – I found comfort in Dr. Taylor’s words: “Mosaicism is more common than we think. Many of us are mosaics without even realizing it. “

After three months, my doctor recommended a blood test, which looked at the baby’s DNA fragments in my blood to see if he was at risk of genetic abnormalities. By this point, my husband and I had started noticing families in the dog park whose children were genetically handicapped. We tacitly found acceptance that we would add variety to the families in our ward and decided not to quit the baby, regardless of the outcome.

They came back as usual. But, like with embryo testing, the blood test could not diagnose a fetus’ genetic condition with any certainty. Our doctor offered a more detailed amniocentesis test, but we had already made our decision. I decided to leave it there.

Now, during the ultrasound, our daughter hides her face behind her hands or presses firmly against the placenta as if asking us to let it grow in privacy. The last time I saw her full profile, her nose was long and sharp, protruding and unmistakable in five months of pregnancy. I wondered if it was one of the features of the extra 22nd chromosome, or if she simply inherited my husband’s nose. As my due date approaches, her genetic profile is less of a concern. I am thrilled that we made it this far.

Categories
Health

The Coronavirus Is Plotting a Comeback. Right here’s Our Likelihood to Cease It for Good.

The Coronavirus Is Plotting a Comeback. Here’s Our Chance to Stop It for Good.

Across the United States, and the world, the coronavirus seems to be loosening its stranglehold. The deadly curve of cases, hospitalizations and deaths has yo-yoed before, but never has it plunged so steeply and so fast.

Is this it, then? Is this the beginning of the end? After a year of being pummeled by grim statistics and scolded for wanting human contact, many Americans feel a long-promised deliverance is at hand.

We will win against the virus and regain many aspects of our pre-pandemic lives, most scientists now believe. Of the 21 interviewed for this article, all were optimistic that the worst of the pandemic is past. This summer, they said, life may begin to seem normal again.

But — of course, there’s always a but — researchers are also worried that Americans, so close to the finish line, may once again underestimate the virus.

So far, the two vaccines authorized in the United States are spectacularly effective, and after a slow start, the vaccination rollout is picking up momentum. A third vaccine is likely to be authorized shortly, adding to the nation’s supply.

But it will be many weeks before vaccinations make a dent in the pandemic. And now the virus is shape-shifting faster than expected, evolving into variants that may partly sidestep the immune system.

The latest variant was discovered in New York City only this week, and another worrisome version is spreading at a rapid pace through California. Scientists say a contagious variant first discovered in Britain will become the dominant form of the virus in the United States by the end of March.

The road back to normalcy is potholed with unknowns: how well vaccines prevent further spread of the virus; whether emerging variants remain susceptible enough to the vaccines; and how quickly the world is immunized, so as to halt further evolution of the virus.

But the greatest ambiguity is human behavior. Can Americans desperate for normalcy keep wearing masks and distancing themselves from family and friends? How much longer can communities keep businesses, offices and schools closed?

Covid-19 deaths will most likely never rise quite as precipitously as in the past, and the worst may be behind us. But if Americans let down their guard too soon — many states are already lifting restrictions — and if the variants spread in the United States as they have elsewhere, another spike in cases may well arrive in the coming weeks.

Scientists call it the fourth wave. The new variants mean “we’re essentially facing a pandemic within a pandemic,” said Adam Kucharski, an epidemiologist at the London School of Hygiene and Tropical Medicine.

The United States has now recorded 500,000 deaths amid the pandemic, a terrible milestone. As of Wednesday morning, at least 28.3 million people have been infected.

But the rate of new infections has tumbled by 35 percent over the past two weeks, according to a database maintained by The New York Times. Hospitalizations are down 31 percent, and deaths have fallen by 16 percent.

Yet the numbers are still at the horrific highs of November, scientists noted. At least 3,210 people died of Covid-19 on Wednesday alone. And there is no guarantee that these rates will continue to decrease.

“Very, very high case numbers are not a good thing, even if the trend is downward,” said Marc Lipsitch, an epidemiologist at the Harvard T.H. Chan School of Public Health in Boston. “Taking the first hint of a downward trend as a reason to reopen is how you get to even higher numbers.”

In late November, for example, Gov. Gina Raimondo of Rhode Island limited social gatherings and some commercial activities in the state. Eight days later, cases began to decline. The trend reversed eight days after the state’s pause lifted on Dec. 20.

The virus’s latest retreat in Rhode Island and most other states, experts said, results from a combination of factors: growing numbers of people with immunity to the virus, either from having been infected or from vaccination; changes in behavior in response to the surges of a few weeks ago; and a dash of seasonality — the effect of temperature and humidity on the survival of the virus.

Parts of the country that experienced huge surges in infection, like Montana and Iowa, may be closer to herd immunity than other regions. But patchwork immunity alone cannot explain the declines throughout much of the world.

The vaccines were first rolled out to residents of nursing homes and to the elderly, who are at highest risk of severe illness and death. That may explain some of the current decline in hospitalizations and deaths.

But young people drive the spread of the virus, and most of them have not yet been inoculated. And the bulk of the world’s vaccine supply has been bought up by wealthy nations, which have amassed one billion more doses than needed to immunize their populations.

Vaccination cannot explain why cases are dropping even in countries where not a single soul has been immunized, like Honduras, Kazakhstan or Libya. The biggest contributor to the sharp decline in infections is something more mundane, scientists say: behavioral change.

Leaders in the United States and elsewhere stepped up community restrictions after the holiday peaks. But individual choices have also been important, said Lindsay Wiley, an expert in public health law and ethics at American University in Washington.

“People voluntarily change their behavior as they see their local hospital get hit hard, as they hear about outbreaks in their area,” she said. “If that’s the reason that things are improving, then that’s something that can reverse pretty quickly, too.”

The downward curve of infections with the original coronavirus disguises an exponential rise in infections with B.1.1.7, the variant first identified in Britain, according to many researchers.

“We really are seeing two epidemic curves,” said Ashleigh Tuite, an infectious disease modeler at the University of Toronto.

The B.1.1.7 variant is thought to be more contagious and more deadly, and it is expected to become the predominant form of the virus in the United States by late March. The number of cases with the variant in the United States has risen from 76 in 12 states as of Jan. 13 to more than 1,800 in 45 states now. Actual infections may be much higher because of inadequate surveillance efforts in the United States.

Buoyed by the shrinking rates over all, however, governors are lifting restrictions across the United States and are under enormous pressure to reopen completely. Should that occur, B.1.1.7 and the other variants are likely to explode.

Updated 

Feb. 25, 2021, 9:03 p.m. ET

“Everybody is tired, and everybody wants things to open up again,” Dr. Tuite said. “Bending to political pressure right now, when things are really headed in the right direction, is going to end up costing us in the long term.”

Looking ahead to late March or April, the majority of scientists interviewed by The Times predicted a fourth wave of infections. But they stressed that it is not an inevitable surge, if government officials and individuals maintain precautions for a few more weeks.

A minority of experts were more sanguine, saying they expected powerful vaccines and an expanding rollout to stop the virus. And a few took the middle road.

“We’re at that crossroads, where it could go well or it could go badly,” said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.

The vaccines have proved to be more effective than anyone could have hoped, so far preventing serious illness and death in nearly all recipients. At present, about 1.4 million Americans are vaccinated each day. More than 45 million Americans have received at least one dose.

A team of researchers at Fred Hutchinson Cancer Research Center in Seattle tried to calculate the number of vaccinations required per day to avoid a fourth wave. In a model completed before the variants surfaced, the scientists estimated that vaccinating just one million Americans a day would limit the magnitude of the fourth wave.

“But the new variants completely changed that,” said Dr. Joshua T. Schiffer, an infectious disease specialist who led the study. “It’s just very challenging scientifically — the ground is shifting very, very quickly.”

Natalie Dean, a biostatistician at the University of Florida, described herself as “a little more optimistic” than many other researchers. “We would be silly to undersell the vaccines,” she said, noting that they are effective against the fast-spreading B.1.1.7 variant.

But Dr. Dean worried about the forms of the virus detected in South Africa and Brazil that seem less vulnerable to the vaccines made by Pfizer and Moderna. (On Wednesday, Johnson & Johnson reported that its vaccine was relatively effective against the variant found in South Africa.)

About 50 infections with those two variants have been identified in the United States, but that could change. Because of the variants, scientists do not know how many people who were infected and had recovered are now vulnerable to reinfection.

South Africa and Brazil have reported reinfections with the new variants among people who had recovered from infections with the original version of the virus.

“That makes it a lot harder to say, ‘If we were to get to this level of vaccinations, we’d probably be OK,’” said Sarah Cobey, an evolutionary biologist at the University of Chicago.

Yet the biggest unknown is human behavior, experts said. The sharp drop in cases now may lead to complacency about masks and distancing, and to a wholesale lifting of restrictions on indoor dining, sporting events and more. Or … not.

“The single biggest lesson I’ve learned during the pandemic is that epidemiological modeling struggles with prediction, because so much of it depends on human behavioral factors,” said Carl Bergstrom, a biologist at the University of Washington in Seattle.

Taking into account the counterbalancing rises in both vaccinations and variants, along with the high likelihood that people will stop taking precautions, a fourth wave is highly likely this spring, the majority of experts told The Times.

Kristian Andersen, a virologist at the Scripps Research Institute in San Diego, said he was confident that the number of cases will continue to decline, then plateau in about a month. After mid-March, the curve in new cases will swing upward again.

In early to mid-April, “we’re going to start seeing hospitalizations go up,” he said. “It’s just a question of how much.”

Now the good news.

Despite the uncertainties, the experts predict that the last surge will subside in the United States sometime in the early summer. If the Biden administration can keep its promise to immunize every American adult by the end of the summer, the variants should be no match for the vaccines.

Combine vaccination with natural immunity and the human tendency to head outdoors as weather warms, and “it may not be exactly herd immunity, but maybe it’s sufficient to prevent any large outbreaks,” said Youyang Gu, an independent data scientist, who created some of the most prescient models of the pandemic.

Infections will continue to drop. More important, hospitalizations and deaths will fall to negligible levels — enough, hopefully, to reopen the country.

“Sometimes people lose vision of the fact that vaccines prevent hospitalization and death, which is really actually what most people care about,” said Stefan Baral, an epidemiologist at the Johns Hopkins Bloomberg School of Public Health.

Even as the virus begins its swoon, people may still need to wear masks in public places and maintain social distance, because a significant percent of the population — including children — will not be immunized.

“Assuming that we keep a close eye on things in the summer and don’t go crazy, I think that we could look forward to a summer that is looking more normal, but hopefully in a way that is more carefully monitored than last summer,” said Emma Hodcroft, a molecular epidemiologist at the University of Bern in Switzerland.

Imagine: Groups of vaccinated people will be able to get together for barbecues and play dates, without fear of infecting one another. Beaches, parks and playgrounds will be full of mask-free people. Indoor dining will return, along with movie theaters, bowling alleys and shopping malls — although they may still require masks.

The virus will still be circulating, but the extent will depend in part on how well vaccines prevent not just illness and death, but also transmission. The data on whether vaccines stop the spread of the disease are encouraging, but immunization is unlikely to block transmission entirely.

“It’s not zero and it’s not 100 — exactly where that number is will be important,” said Shweta Bansal, an infectious disease modeler at Georgetown University. “It needs to be pretty darn high for us to be able to get away with vaccinating anything below 100 percent of the population, so that’s definitely something we’re watching.”

Over the long term — say, a year from now, when all the adults and children in the United States who want a vaccine have received them — will this virus finally be behind us?

Every expert interviewed by The Times said no. Even after the vast majority of the American population has been immunized, the virus will continue to pop up in clusters, taking advantage of pockets of vulnerability. Years from now, the coronavirus may be an annoyance, circulating at low levels, causing modest colds.

Many scientists said their greatest worry post-pandemic was that new variants may turn out to be significantly less susceptible to the vaccines. Billions of people worldwide will remain unprotected, and each infection gives the virus new opportunities to mutate.

“We won’t have useless vaccines. We might have slightly less good vaccines than we have at the moment,” said Andrew Read, an evolutionary microbiologist at Penn State University. “That’s not the end of the world, because we have really good vaccines right now.”

For now, every one of us can help by continuing to be careful for just a few more months, until the curve permanently flattens.

“Just hang in there a little bit longer,” Dr. Tuite said. “There’s a lot of optimism and hope, but I think we need to be prepared for the fact that the next several months are likely to continue to be difficult.”

Categories
World News

In Israeli Election, a Probability for Arabs to Achieve Affect, or Lose It

In Israeli Election, a Chance for Arabs to Gain Influence, or Lose It

KAFR KANNA, Israel – Mansour Abbas, a conservative Muslim, is an unlikely political partner for the leaders of the Jewish state.

He is a proponent of political Islam. He heads an Arab party stemming from the same religious stream that gave birth to the militant Hamas movement. And for most of his political life, he never thought of supporting the right-wing parties that have led Israel for the most part for the past four decades.

If Abbas has his way, he could help appoint the next Israeli prime minister after next month’s general election, even if that means a right-wing alliance will come back to power. Tired of the peripheral role of Israel’s Arab parties, he hopes that his small Islamist group, Raam, will keep the balance of power after the elections and prove to be an inevitable partner for any Jewish leader who wants to form a coalition.

“We can work with anyone,” said Abbas in an interview on the campaign in Kafr Kanna, a small Arab town in northern Israel, at the point where, according to the Christian Bible, Jesus turned water into wine. In the past, “Arab politicians have been spectators in Israel’s political process,” he said. Now he added: “Arabs are looking for a real role in Israeli politics.”

The move of Mr Abbas is part of a wider change within the Arab political world in Israel.

Accelerated by the election campaign, two trends converge: On the one hand, Arab politicians and voters increasingly believe that in order to improve the lives of Arabs in Israel, they must seek power within the system rather than exerting external pressure. Regardless, mainstream Israeli parties recognize that they need to attract Arab voters to win a very close election – and some are willing to work with Arab parties as potential coalition partners.

Both trends are due to political pragmatism rather than dogma. And while the moment has the potential to give real power to Arab voters, it could backfire: Abbas’ actions will split the Arab vote, as will the overtures of Jewish-led parties, and both factors could increase the number of Arab legislators in the EU lower next parliament.

But after a strong performance in the last election, in which Arab parties won a record 15 seats, becoming the third largest alliance in parliament with 120 seats and still being excluded from the ruling coalition, some are looking for other options.

“After more than a decade with Netanyahu in power, some Arab politicians have suggested a new approach: if you can’t beat him, join him,” said Mohammad Magadli, a well-known Arab TV host. “This approach is brave, but also very dangerous.”

Palestinian citizens of Israel make up more than a fifth of the Israeli population. Since the founding of the state in 1948, they have always sent a handful of Arab legislators to parliament. But these lawmakers have always fought to make a difference.

Jewish leaders have not seen Arab parties as acceptable coalition partners – some right-wing denigrate them as enemies of the state and seek the suspension of Arab lawmakers from parliament. Arab parties have generally felt more comfortable in the opposition, rarely supporting center-left parties, whose influence has waned since the beginning of the century.

In some ways, that dynamic has deteriorated in recent years. In 2015, Prime Minister Benjamin Netanyahu referred to the danger of a relatively high Arab turnout: “Arab voters flock to the polling stations in large numbers,” he warned on election day in order to scare his base for voting. In 2018, his government passed new laws downgrading the status of Arabs and officially designating Israel as the nation-state of the Jewish people only. And in 2020, even his centrist rival Benny Gantz refused to form a government based on the support of Arab parties.

But a year later, when Israel goes to its fourth election in two years of political blockade, that paradigm changes rapidly.

Mr Netanyahu is now vigorously campaigning for Arab voters. Yair Lapid, a centrist candidate for the prime ministry, said he could form a coalition with Arab lawmakers despite belittling them early in his career. Two left-wing parties have promised to work with an alliance of Arab lawmakers to advance Arab interests.

According to polls, a majority of Israel’s Palestinian citizens want their lawmakers to play a role in government. Abbas says Arab politicians should gain influence by supporting parties that promise to improve Arab society. Another prominent Arab politician, Ali Salam, the Mayor of Nazareth, Israel’s largest Arab city, has expressed support for Mr Netanyahu, arguing that despite his previous comments, the Prime Minister is genuinely interested in improving Arab life.

“It used to be a sin in Israel’s political system to work with Arab parties or even Arab voters,” said Nahum Barnea, one of Israel’s best-known columnists. But Mr. Netanyahu has suddenly made Arabs “a legitimate partner for any political maneuver”.

“In a way, he opened a box that hopefully won’t be able to be closed from now on,” added Barnea.

Mr. Netanyahu’s transition was one of the most notable. He pledged more resources for Arab communities and the fight against endemic crime in Arab neighborhoods. And he has started to call himself “Yair’s father” – a reference to his son Yair, who also speaks lovingly about the Arab practice of referring to someone as the parent of their firstborn child.

At a turning point in January, he announced a “new era” for Arab Israelis at a rally in Nazareth and made a qualified apology for his earlier comments on Arab voters. “I apologized then and I apologize today,” he said before adding that critics “twisted my words.”

Critics say Mr. Netanyahu woos Arab voters because he needs them to win, not because he genuinely cares about them. This month he also agreed to add a far-right party to his next coalition whose leader wants many Arabs to be banned from running for parliament. And he has ruled out the formation of a government that depends on Mr. Abbas’ support.

Next month’s elections are expected to be as close as the previous three.

Mr. Netanyahu is currently on trial on corruption charges. If he stays in power, he could pursue laws that protect him from prosecution.

“What interests Netanyahu is Netanyahu,” said Afif Abu Much, a prominent commentator on Arab politics in Israel.

Likewise, Arab politicians and voters have not filed all complaints about Zionism and Israeli politics in the occupied territories. However, there is a growing awareness that problems in the Arab community – gang violence, poverty and discrimination in access to housing and land – cannot be solved without Arab politicians shaping politics at the highest level.

“I want different results, so I have to change the approach,” said Abbas. “The crises in Arab society have reached a boiling point.”

However, Mr Abbas’ plan could easily fail and undermine the little influence of Arab citizens.

In order to run on his new platform, Mr. Abbas had to withdraw from an alliance of Arab parties, the Joint List, whose remaining members are not convinced that they are cooperating with the Israeli right. And that split could dilute the collective power of Arab lawmakers.

Support for Mr Abbas’ party is currently close to the 3.25 percent threshold the parties need to secure entry into parliament. Even if his party scrapes over the line, there is no guarantee that a candidate for Prime Minister will need or seek the party’s support to secure the 61 seats required to form a coalition.

Mr Netanyahu, despite his previous incitement to Arabs, could also pull Arab voters away from Arab parties and reduce their influence. Even more could stay at home, disaffected by the divisions within the Arab parties and their inability to bring about meaningful change or to boycott a state whose authority they reject.

“I don’t believe in or trust any of them,” said Siham Ighbariya, a 40-year-old housewife. She became known for seeking justice for her husband and son, who were murdered at home by an unknown murderer in 2012.

“I’ve looked at all of them,” Ms. Ighbariya said of the Arab political class. “And nothing happened.”

For some Palestinians, participation in the Israeli government is a betrayal of the Palestinian cause – a criticism Abbas understands. “I have this deep personal conflict within me,” he admitted. “We have been in a conflict for 100 years, a bloody and difficult conflict.”

But it was time to move on, he added. “You have to be able to look into the future and create a better future for everyone, both Arabs and Jews.”

Categories
Business

CVS and Walgreens have an opportunity to make Covid vaccine rollout extra equitable

Widespread Covid vaccines will be available in the spring, says Walgreens exec

Dr. Virginia Banks, eine Spezialistin für Infektionskrankheiten, gehört zu einer Gruppe schwarzer Ärzte und Wissenschaftler, die sich auf Möglichkeiten zur Lösung von Disparitäten im Gesundheitswesen konzentrieren.

Dr. Virginia Banks

Dr. Virginia Banks sagt, wenn die USA die Pandemie wirklich beenden wollen, werden sie mobile Transporter mit Impfstoffen in Gegenden nehmen, in denen die Menschen keinen Transport haben – und sogar in Friseursalons und Friseurläden schießen.

Da Tausende von Apotheken diese Woche Dosenlieferungen erhalten und Impfungen in ihren Läden beginnen, unternimmt das Land einen bedeutenden Schritt, um mehr Amerikaner zu erreichen. Beamte und Anwälte des öffentlichen Gesundheitswesens sagen jedoch, dass dies in Gemeinden, in denen die Menschen am kranksten waren, nicht weit genug gehen wird.

Weitere schwarze und hispanische Amerikaner wurden ins Krankenhaus eingeliefert und starben an Covid-19. Sie sind oft auch mit größeren Hindernissen konfrontiert, um Impfstoffe zu erhalten: Mangel an Transportmitteln. Ein Jonglieren mit mehreren Jobs. Zögern wegen Misshandlung durch die medizinische Gemeinschaft in der Vergangenheit.

CVS Health und Walgreens werden eine größere Rolle bei den Bemühungen spielen, da ein Bundesprogramm Dosen an mehr ihrer Geschäfte und die anderer Einzelhandelsapotheken versendet. Die Erweiterung stellt eine Geschäftsmöglichkeit für die beiden größten Apothekenketten des Landes dar, da sie für jeden Impfstoff bezahlt werden und mehr Fußgängerverkehr in die Geschäfte bringen. Der Impfstoff-Rollout wird auch das Engagement der Unternehmen für die Ausweitung des Zugangs zur Gesundheitsversorgung in schwarzen und hispanischen Gemeinden testen.

Banks, ein Arzt für Infektionskrankheiten in Ohio, ist Teil einer Interessengruppe der Infectious Diseases Society of America, die sich aus schwarzen Ärzten, Wissenschaftlern und Beamten des öffentlichen Gesundheitswesens zusammensetzt, die sich mit der Beseitigung von Disparitäten im Gesundheitswesen befassen. Sie sagte, dass Gesundheitsdienstleister kreativ werden und Engagement zeigen müssen. Sie sagte, sie sollten Kliniken an vertrauten Orten wie Kirchen einrichten und “vertrauenswürdige Boten” wie Pastoren und Gemeindevorsteher gewinnen.

“Man muss sich aus kultureller Sicht ansehen, wo wir sind.” und komm zu uns “, sagte sie.

Mehr als Fairness

Die Einführung des Impfstoffs in den USA war langsam und komplex. Die Nachfrage nach Dosen hat die Anzahl der Schüsse, die zum Einstechen in die Arme zur Verfügung stehen, bei weitem überwogen. Online-Terminsysteme waren schwierig zu navigieren und wurden von starkem Verkehr blockiert. Bisher haben nur zwei Impfstoffe eine Notfallgenehmigung der Food and Drug Administration und müssen bei kalten und ultrakalten Temperaturen gelagert werden. Und nur einige Amerikaner qualifizieren sich für den Schuss, wobei jeder Staat leicht unterschiedliche Kriterien hat, um Faktoren wie Alter, Gesundheitszustand oder Arbeit einer Person abzuwägen.

Laut den Centers for Disease Control and Prevention wurden in den USA bis Freitag etwa 48,4 Millionen Impfstoffe verabreicht. Fast 12,1 Millionen Menschen haben beide Dosen des Impfstoffs erhalten – nur ein kleiner Teil der 331 Millionen Menschen, die in den USA leben

Das Ziel des Landes ist es, zwischen 70% und 85% der US-Bevölkerung – oder etwa 232 bis 281 Millionen Menschen – zu impfen, um eine Herdenimmunität zu erreichen, so Dr. Anthony Fauci, der Chefarzt des Präsidenten.

Personen ohne Termin stehen an, um möglicherweise eine Dosis des Pfizer-BioNTech Covid-19-Impfstoffs zu erhalten, nachdem alle Termine am Donnerstag, dem 11. Februar 2021, an der Impfstelle des Sun City Anthem Community Center in Henderson, Nevada, verabreicht wurden.

Roger Kisby | Bloomberg | Getty Images

Der chaotische Rollout hat dazu geführt, dass einige Aufnahmen gemacht haben und andere nicht. Laut einer CDC-Studie waren die meisten der fast 13 Millionen Menschen, denen innerhalb des ersten Monats nach der Verteilung der Medikamente mindestens ein Schuss eines Covid-19-Impfstoffs verabreicht wurde, Frauen im Alter von 50 Jahren oder älter und wahrscheinlich nicht spanisch und weiß.

Bei der Verteilung von Impfstoffen ist Gerechtigkeit nicht nur eine Frage der Fairness. Dies ist auch ein entscheidender Weg, um die Ausbreitung in Gemeinden zu verlangsamen, in denen Covid-19-Fälle, Krankenhausaufenthalte und Todesfälle häufiger auftreten. Schwarze und hispanische Amerikaner werden nach Angaben der CDC Ende November 3,7-mal und 4,1-mal häufiger aus Covid ins Krankenhaus eingeliefert als weiße Amerikaner. Beide Minderheiten sterben 2,8-mal häufiger an der Krankheit als weiße Amerikaner.

In einem stark betroffenen Viertel kann die Wirkung jedes Schusses noch größer sein – Menschen erreichen, die einem höheren Risiko ausgesetzt sind, wenn sie in Lebensmittelgeschäften oder an anderen Arbeitsplätzen an vorderster Front arbeiten oder in einer dichten Wohnung oder in Haushalten mit mehreren Generationen leben.

Das Zögern bei Impfungen ist auch bei Schwarzen und Braunen höher, was auf die Geschichte der medizinischen Gemeinschaft zurückzuführen ist, in der Minderheiten misshandelt und weniger Gesundheitspraktiken in ihrer Nachbarschaft eröffnet wurden. Eine von der Association for a Better New York durchgeführte Umfrage unter New Yorkern ergab, dass 78% der Einwohner von White den Impfstoff so schnell wie möglich einnehmen würden, verglichen mit 39% der Einwohner von Black, 54% der Hispanics und 54% der Asiaten .

“Setzen Sie ihr Geld, wo ihr Mund ist”

Für Anbieter wie CVS und Walgreens ist es eine Geschäftsmöglichkeit, mehr Dosen des Impfstoffs zu haben. Sie werden für jeden Impfstoff bezahlt und die Regierung übernimmt die Kosten, wenn eine Person nicht krankenversichert ist. Jefferies schätzte, dass jeder Schuss eine Bruttomarge von 13 bis 15 US-Dollar haben wird und im nächsten Jahr einen zusätzlichen Bruttogewinn von etwa 1 Milliarde US-Dollar für CVS bringen könnte.

Beide Drogerieketten haben ihre Strategie festgelegt, mehr Gesundheitsdienstleistungen von Kliniken für Grundversorgung zu Diabetes-Screenings hinzuzufügen. Sie haben auch ihre Verpflichtungen zur Beseitigung von Rassenungleichheiten als Reaktion auf George Floyds Mord und landesweite Proteste verstärkt. CVS plant, über einen Zeitraum von fünf Jahren fast 600 Millionen US-Dollar zu investieren, um politische Initiativen und interne Bemühungen zu unterstützen, z. B. die Betreuung schwarzer Mitarbeiter und kostenlose Gesundheitsuntersuchungen auf Blutdruck und Cholesterin in Geschäften.

Walgreens startete ein Pilotprojekt in der Region Chicago, das darauf abzielt, die Krankenhausaufenthaltsraten zu senken, indem es Patienten erleichtert wird, ihre Medikamente einzunehmen, kostenlose Verschreibungen zu erhalten und regelmäßiger mit Angehörigen der Gesundheitsberufe über ihren Gesundheitszustand in Kontakt zu treten. Das Unternehmen hat kürzlich den ehemaligen Chief Operating Officer von Starbucks, Roz Brewer, als nächsten CEO eingestellt. Wenn sie Mitte März in die Rolle eintritt, wird sie nur eine schwarze Frau sein, die ein Fortune 500-Unternehmen leitet.

Karyne Jones, Der CEO des National Caucus and Center on Black Aging in Washington, DC, sagte, die Ausweitung von Impfstoffen auf schwer betroffene Gemeinden sei eine Möglichkeit für CVS und Walgreens, “ihr Geld dort einzusetzen, wo ihr Mund ist”. Ihre Organisation ist Gründungsmitglied des Covid-19 Vaccine Education and Equity Project, einer Koalition von gemeinnützigen Organisationen und Handelsgruppen, die vom Impfstoffhersteller Pfizer unterstützt wird.

Jones sagte, sie würde gerne sehen, wie CVS und Walgreens rund um die Uhr Impfstellen öffnen und Zelte in Gegenden aufbauen, in denen die Menschen keinen Transport haben.

“Wenn Sie wirklich gute unternehmerische Verantwortung zeigen wollen, ist dies die Zeit zu sagen, dass wir Ressourcen einsetzen müssen, um diese Pandemie zu lindern”, sagte sie.

Wir haben Apothekenwüsten. Wir haben Wüsten für Lebensmittelgeschäfte. Wir haben keine kirchlichen Wüsten.

Dr. Virginia Banks

Spezialist für Infektionskrankheiten

Banks, der Arzt für Infektionskrankheiten, sagte, er werde über den Tellerrand hinaus Strategien verfolgen, wie beispielsweise die Umleitung von Buslinien zu Impfkliniken. Sie wies auf eine Anstrengung hin, bei der sich Apotheker mit Friseurläden zusammengetan hatten, um Bluthochdruck zu erkennen, als schwarze Männer einen Haarschnitt machten – eine klinische Studie, die half, den Zustand zu erkennen und früher einzugreifen.

Sie sagte, sie hoffe, dass der Johnson & Johnson-Impfstoff – der nur eine Dosis benötigt und leichter transportiert werden kann – die Verteilung verändern und es einfacher machen könnte, Schüsse dort abzugeben, wo sich Menschen befinden. Das Unternehmen hat letzte Woche bei der FDA eine Genehmigung für den Notfall beantragt.

“Wir haben Apothekenwüsten”, sagte sie. “Wir haben Wüsten für Lebensmittelgeschäfte. Wir haben keine Wüsten für Kirchen.”

Dosen in mehr Stadtteilen

Walgreens und CVS haben in Tausenden von Pflegeheimen und Einrichtungen für betreutes Wohnen Covid-Impfstoffe verabreicht. Sie haben in einigen Geschäften Schüsse verabreicht, nachdem sie Impfstoffdosen von Staaten erhalten hatten. Mit dem Bundesprogramm werden sie Aufnahmen in mehr Stadtteilen anbieten.

Walgreens hat Covid-Impfstoffe in Geschäften in 15 Bundesstaaten und zwei weiteren Gerichtsbarkeiten, New York City und Chicago. Im Rahmen des Bundesprogramms werden Aufnahmen in 1.800 Filialen gemacht – oder rund 20% der US-Filialen, sagte eine Unternehmenssprecherin.

CVS hat sie in 18 Staaten und Puerto Rico. Ab Freitag werden rund 420 der rund 9.900 Filialen die Aufnahmen mit Dosen eines staatlichen oder föderalen Programms machen, sagte ein Unternehmenssprecher.

Beide Apothekenketten gaben an, Geschäfte in Gegenden mit größerem Bedarf ausgewählt zu haben. Etwa die Hälfte der Geschäfte jedes Unternehmens mit Covid-Impfstoffen befindet sich in medizinisch unterversorgten Gebieten oder an Orten, die auf dem CDC-Index für soziale Anfälligkeit einen hohen Stellenwert haben. Dieser basiert auf Faktoren wie der Verbreitung von Armut, mangelndem Zugang zu Fahrzeugen und überfüllten Wohnungen.

Mit Walgreens können Personen auch Termine persönlich oder telefonisch vereinbaren, sodass Personen nicht ausgeschlossen werden, wenn sie kein Internet oder keinen Computer haben, sagte Rina Shah, Vizepräsidentin der Walgreens-Gruppe für Apothekenbetriebe. CVS hat eine 1-800-Nummer als Alternative zur Online-Buchung.

Walgreens ging eine Partnerschaft mit Uber ein, um Menschen, die in unterversorgten Teilen von Großstädten wie Atlanta und Chicago leben, kostenlose Fahrten zu Impfungen zu ermöglichen. Wohltätige Partner helfen bei der Identifizierung von Personen, die Transport benötigen.

CVS unternimmt proaktive Schritte, um sicherzustellen, dass die Einheimischen Impfstofftermine in ihrem nahe gelegenen Geschäft erhalten können, sagte Chris Cox, Senior Vice President für Pharmazie des Unternehmens. Er sagte, dass Mitarbeiter einige Kunden anrufen, um ihre Termine zu vereinbaren, insbesondere diejenigen, die ein niedrigeres Einkommen haben und älter sind.

Zusammen mit der Anwerbung von Apotheken wird die Biden-Regierung nächste Woche Dosen an kommunale Gesundheitszentren liefern, die Millionen von Amerikanern dienen, die unterhalb der Armutsgrenze leben und rassische Minderheiten sind.

Das Impfprogramm ermöglicht es CVS, eindringlich zu demonstrieren, wie es Gesundheitsversorgung an Orten anbieten kann, an denen es normalerweise nicht zugänglich ist, sagte Cox.

“Alles, was wir tun, ist wirklich mit der Absicht, Menschen auf ihrem Weg zu einer besseren Gesundheit zu helfen”, sagte er. “Diese Gelegenheit bietet uns wirklich, unseren Patienten und anderen Interessengruppen zu demonstrieren, was wir seit mehreren Jahren sagen. Das heißt, dass die Gemeinschaftsapotheke eine große Rolle im Gesundheitswesen spielt.”

Viele Patienten sehen ihre Apotheker häufiger als ihre Ärzte, da sie Bluthochdruckpillen oder andere Erhaltungsrezepte abholen müssen, sagte er. Diese häufigen Wechselwirkungen bedeuten, dass CVS eine größere Rolle dabei spielen kann, sicherzustellen, dass Menschen ihre Medikamente richtig einnehmen, oder vor möglichen Komplikationen eingreifen kann.

Da Walgreens mehr Angebot erhält, wird Shah seine Arbeitszeiten verlängern und an Wochenenden Aufnahmen für Leute anbieten, die keinen Arbeitstag auslassen können. Es wird Kliniken in Gemeindezentren eröffnen, wie es bei Grippeschutzimpfungen der Fall ist.

Shah sagte, dass seine Apotheker eine Schlüsselrolle bei der Aufklärung und Beantwortung von Fragen spielen können, so dass die Leute eher auf die Aufnahmen gespannt sind als besorgt. Aber sie sagte, das Unternehmen brauche letztendlich mehr Versorgung, um mehr Menschen in Minderheitengemeinschaften zu erreichen.

“Unsere größte Chance ist es, mehr Impfstoffe zu bekommen”, sagte sie.

Categories
Entertainment

New Star of ‘The Promenade’ Sees a Probability to Make L.G.B.T.Q. Characters Seen

New Star of ‘The Prom’ Sees a Chance to Make L.G.B.T.Q. Characters Visible

During her second day on a movie set, Jo Ellen Pellman ran into an angry Meryl Streep.

“You owe me a house!” Streep, a three-time Oscar winner, growled with twinkling eyes as she removed her blazer and pounced on 24-year-old Ingénue.

Pellman’s eyes widened. “I am sorry!” she said and raised her hand apologetically.

“And cut!”

Pellman played Emma Nolan, a schoolgirl in a narrow-minded Indiana town who wants to take her friend to prom in the Netflix adaptation of the musical “The Prom”. Like Emma, ​​Pellman is a Midwestern who identifies as queer. But unlike her character, the young actress grew up in a supportive environment that influenced her view of the movie’s potential.

“For young people who identify as LGBTQ, I hope it can be a two-hour break from everything that’s happening in the world,” she said. “Like, ‘It’ll be fine, my people are out there.'”

Even so, this is her first film role, it happens to be the lead role, and her co-stars – including Streep, James Corden, and Nicole Kidman as Narcissistic Broadway actors who parachute in to help their character – are names among those she looked up for a long time.

Pellman projected full confidence in the stars’ presence, said Ryan Murphy, the film’s director. “She wasn’t afraid,” although her experience until then consisted of roles like Girl # 2 in an episode of “The Marvelous Mrs. Maisel”.

Meanwhile, Murphy, whose credits include American Horror Story and Pose, said, “I was so nervous when I first directed Meryl Streep – I think I did four takes. I was trembling. “

Pellman said she was barely immune to Streep’s stellar power. “I love how it came across,” she said, grinning from home in Cincinnati, where she has lived with her mother since March, during a Zoom interview last month. “Inside I was like ‘OMG, this is Meryl Streep!'”

It took Murphy a single meeting to decide Pellman was his Emma.

“I saw your tape and I knew it,” he said. “She had this mixture of soul and sperm and mind – and that amazing smile.”

Pellman, a graduate of the University of Michigan, was working three jobs opening calls in New York City upon hearing of the nationwide search for the role. “It felt like a long shot,” she said. But Pellman, a strange woman herself, felt Emma’s optimism and determination when she saw the play on Broadway starring Caitlin Kinnunen.

She didn’t know until shortly before meeting Murphy that Ariana DeBose, who plays Emma’s friend Alyssa Green, would be the only other actress there. “I saw Ariana’s name on the call sheet and I freaked out because she’s someone I’ve looked up to throughout my career,” she said.

But Murphy said when Pellman was nervous, she wouldn’t let up. “As soon as Jo Ellen started talking about her life, she didn’t even have to read,” he said. “She spoke very movingly about being a strange woman and having a gay single mother to raise her. I remember she left and I just thought, ‘Thank god this is over – we found our girl.’ “

Pellman was less sure. But she got a hint about her interview. “He hugged us at the end of foreplay,” she said. “When does that ever happen? A hug from Ryan Murphy? That’s huge! “

When Murphy called the next day to tell Pellman that she had gotten her dream role, she was reading the coats at a thrift store in Bushwick. The first person she called was her mother. Or rather tried.

Monica Pellman didn’t answer.

It was a rare absence for the woman Pellman blames for raising her in a supportive, LGBTQ-approved household – an experience she is grateful for deviating from Emma’s. “When I graduated from high school, it wasn’t a big deal,” she said. “I just blew out while watching TV one night.” Mom i think i’m weird “And she said,” That’s perfectly fine. “She just wanted me to be happy.”

Pellman’s mother, who calls her “pretty much the coolest person ever,” declined to be interviewed for this article. But she was invisible during our conversation in November and laughed at her daughter’s admission that she was fluent in Ubbi Dubbi, the gibberish language popularized by the PBS program Zoom, and handed Pellman handkerchiefs as she talked about an emotional moment The film in which Emma explains that she has never felt so alone in her life.

Unlike Emma, ​​Pellman wasn’t an outcast who grew up in Cincinnati, a far cry from Edgewater, Indiana, the fictional setting for the film. She describes her high school as “fairly progressive”. Most of her close friends were gay, she said, adding, “I’m lucky because I’ve never been bullied.”

It was this confirmation from which she drew Emma in her portrayal as a powerful – albeit reluctant – leader who makes her own as the film progresses. “It’s the best feeling in the world to know that I can bring my real self into the role,” Pellman said. “And not just accepted, but celebrated.”

“When she called to tell me she got the role, there was a certain rightness in the world,” said Brent Wagner, who recently retired as chairman of the musical theater department at the University of Michigan. “Because if she hadn’t got it, she’d be out there fighting for the Emma’s of the world.”

She and DeBose, a queer woman who Pellman calls “the one person who always knows exactly what I’m going through,” founded the Unruly Hearts Initiative to connect young LGBTQ people with organizations that help provide housing, mental health services and mentoring help.

This isn’t the only time she has shared her talents. In 2017 she traveled to India and led theater workshops in Mumbai with imprisoned women and victims of human trafficking.

Pellman proudly points out that this is not her first appearance in the New York Times. She was featured in a 2019 article about a battle to get a refund of the $ 1,200 she and her roommate paid in dubious apartment registration fees.

“And I won!” She said.

Despite the praise she recently received – Kidman referred to her “1940s movie star face” in an email – Pellman has Selina Meyer’s mouth. “During the scene in which all these evasive balls were thrown at me by crew members, I was hit very hard in the face,” she said, reflexively yelling a nickname back. “It was very funny. Everyone laughed.”

DeBose, 29, said Pellman was the person on set who brought people together – and she speaks regularly on FaceTime. “She’s Emma 2.0,” she said. “She’s great at fellowship, and she’s the person who got the troops together.”

For her part, Pellman said she hopes the film speaks directly to young people who identify as LGBTQ. “I hope they say, ‘I’m worthy of a happy ending,” she said.

Categories
Business

Zoom Lessons. No Probability Conferences. Is Digital Enterprise College Well worth the Value?

Zoom Classes. No Chance Meetings. Is Virtual Business School Worth the Cost?

“I feel very happy,” he said. “The pandemic has forced me to think about my priorities as well. I could step back and pause and ask, ‘What do you really want to do?’ “

Mrs. Reichert had the opposite experience. She did an internship at Chewy, the pet food website, last summer from her parents’ home in Spotsylvania County, Virginia – 1,000 miles from Chewy’s headquarters in Dania Beach, Florida. While she praised the company for its efforts to make the most of a bad situation, she decided to return to the consultation.

Networking is a big part of the MBA experience. It’s the component that could pay the most dividends well after closing. But in a virtual or socially distant world it got stunted.

“The social component was disappointing,” said Emma Finkelstein, a sophomore at the University of Virginia’s Darden School of Business. “When I’m a floating head at Zoom, I will have a different relationship with my professors and classmates than in social situations.”

Mr Garg, who describes himself as an introvert, said he had pushed himself to get out.

“It’s a lot about being proactive,” he said. “I’ve had coffee with people. It takes a lot of effort. There are some days when you don’t want to do this. But then you realize that you’ve been home for three days and haven’t seen anyone. “

And it’s not just less sociable students who feel left out of the social aspect of business school. International students who have not been able to return to the USA and students from underrepresented minority groups are also affected.

“Of course, I would say that the impact of the pandemic on the nature of informal networking on our campus could be more impactful for students who, for some reason, felt less enclosed among their MBA peers,” said Dr. Rockoff from Colombia. “These missed opportunities for networks and connections will have a significant impact on them.”

Categories
Health

Trump Administration Handed on Probability to Safe Extra of Pfizer Vaccine

Trump Administration Passed on Chance to Secure More of Pfizer Vaccine

michael barbaro

Hey, it’s Michael. We know that 2020 has been a difficult year. But it’s also been a year of small victories, personal milestones, and moments of joy. If something good happened to you, we want to hear about it. So write us an email or better yet, send us a voice memo to thedaily@nytimes.com— that’s thedaily@nytimes.com— and tell us your story of good news this year, large or small. And thank you. From The New York Times, I’m Michael Barbaro. This is The Daily.

[music]

Today: From the start of the pandemic, the Trump administration said it was committed to ordering and stockpiling enough vaccine to end the pandemic as quickly as possible. But new reporting from The Times raises questions about whether it has actually done that. I spoke with my colleague, Sharon LaFraniere.

It’s Thursday, December 10.

So Sharon, tell me about this tip that you got.

sharon lafraniere

So it was on Saturday. I think I was playing bridge on my phone with the robots, which is how we spend Saturday nights now, right?

michael barbaro

Right.

sharon lafraniere

And I got a call from another New York Times reporter, mutual friend of ours, saying, I have heard this about Pfizer. You need to call this guy. Here’s his name. Here’s his number. Tell him you know me. And so I called the guy, and basically the tip was that the administration had muffed a chance to buy more of Pfizer’s vaccine, and now it couldn’t get it until, like, the middle of next year.

michael barbaro

Hm, that’s a very big tip.

sharon lafraniere

It’s a big tip because Pfizer’s vaccine has been shown to be 95 percent effective, and it’s the first one out of the gate, right? The Brits are already inoculating people with it. The Americans want it. And if we somehow missed out a chance to get twice as many doses as we had locked in, that would be a big deal.

michael barbaro

And I wonder what you thought when you heard this tip. I mean, it’s one of those things you hear, you’re sort of like, wait, could that be right?

sharon lafraniere

My reaction was, if this is right, it’s a big story.

michael barbaro

Mhm. And so what did you do?

sharon lafraniere

So I called my editors and my colleagues and said, we need to chase this as hard as we can. And so all Sunday we were calling everybody, and we’re getting like, sorry, can’t help you on this. Or, I never heard about this. Or, try some other people. And then finally on Monday afternoon, early Monday afternoon, we’re able to confirm it, that in fact Pfizer had tried to get the US government to lock in a hundred million extra doses but the government had turned them down.

[music]michael barbaro

So Sharon, what did you find out was the thinking behind this decision— which feels like a real head-scratcher on paper— not buying extra doses of a very effective vaccine from Pfizer?

sharon lafraniere

So to answer that, we really have to go back to the start of the administration’s whole crash program to develop vaccines, all the way back to March when it starts this initiative called Operation Warp Speed and comes up with a strategy to develop vaccines in record-breaking time.

michael barbaro

Right.

sharon lafraniere

So the initial strategy was that the government would pick three different technologies. And each technology would be pursued by a pair of companies, so six companies all together— six horses. They actually called them horses. And the idea of having a pair of companies is if one company fails, then you’ve still got one company standing to go after that technology. But nobody had any idea which of those vaccine technologies would work. So the government’s strategy was, we’ll back all six, and we’re going to pay this money even before we know whether the vaccines work or not.

But Pfizer was alone among the group in saying, we don’t want your money. And there’s really three reasons for that. So the C.E.O., Albert Bourla, told us, number one, it doesn’t need the money. Number two, it doesn’t want the government oversight. I mean, he actually felt that having government oversight over the vaccine project would not speed them up but it would slow them down. And number three, he was fearful about getting involved in the whole political drama that was starting to unfold with the White House pressuring the health agencies to act in one way or another. He just wanted to stay out of the political fray. And he thought if he takes the money, the money will come with strings attached, and he doesn’t want to be dragged into this.

michael barbaro

Got it. So what exactly is the arrangement with Pfizer? Because it sounds very different from the other five. What’s the eventual terms of it?

sharon lafraniere

So the contract called for Pfizer to deliver a hundred million doses to the U.S. government at a cost of $19.50 per dose by the end of the first quarter of 2021, but the U.S. government didn’t pay any money up front. In other words, only if this vaccine clears all the hurdles, gets approved by the F.D.A., and Pfizer’s able to manufacture it— only in that case will the US government have to actually pay the bill.

michael barbaro

Hm. So in some ways, this arrangement with Pfizer is better for the U.S. government than its arrangement with the five other companies. Doesn’t have to put any money down, and it seems like Pfizer is assuming most, if not all, of the risk.

sharon lafraniere

Exactly.

michael barbaro

This is a very good deal if you’re the United States government.

sharon lafraniere

Right. You get to lock in a hundred million doses, and you don’t have to pay up front.

michael barbaro

And so the U.S. takes that deal.

sharon lafraniere

Right.

michael barbaro

And when exactly was this?

sharon lafraniere

So the contract is signed in late July. But even at that time, we’re told, Pfizer is asking Operation Warp Speed officials, don’t you want more? Like, don’t you want to lock in an extra 100 million doses or 200 million doses? Because you don’t have to pay for them unless it works. And the answer was, no, we’re hedging our bets. We’ve got six candidates here. We’re not playing favorites among any of them. And Pfizer’s saying basically, yeah, but with us, it’s a free bet. But the government is saying, no, we’re sticking with our strategy. They don’t want to bet too heavily on any one of the six, even if the bet is free.

michael barbaro

And Sharon, as the U.S. government is turning down this offer from Pfizer, what does it actually know about Pfizer’s vaccine and how effective it may actually be?

sharon lafraniere

Well, remember this is July, and at this point, the government really doesn’t know very much, if anything, about which of these vaccines is going to work. But as time went on, it looks like suddenly that Pfizer is going to be the first over the finish line. But the problem is, a lot of other countries were also getting interested in Pfizer’s vaccine. They have a vaccine that is attracting so much attention that their executives are getting messages over LinkedIn from other countries, like, we want some. Can we lock this in?

And in early October, the U.S. government also gets interested in some extra doses and talks resume. But it’s no longer the same situation, because while the U.S. was hesitating, other countries were moving in. So in October, they don’t actually come to any agreement on a second contract because the U.S. is like, we need it sooner than it sounds like you’re delivering it. Or, you’re not promising us that we’re going to get it in time. Anyway, the talks are inconclusive. And then comes the big day of November 8.

archived recording

This is CNN breaking news. Pharmaceutical giant Pfizer reportedly making an enormous breakthrough with its Covid-19 vaccine, announcing today—

sharon lafraniere

Pfizer gets the interim results of its clinical trials.

archived recording

Pharmaceutical giant Pfizer just announced moments ago that its coronavirus vaccine is 95 percent effective. 95 percent effective— 95 percent effective, and they say with no serious side effects.

sharon lafraniere

And they are amazing.

archived recording

Pfizer’s C.E.O. is calling it, quote, “the greatest medical advancement in the last 100 years.” We will speak with—

michael barbaro

I remember that, Sharon. The results were stunning. And it suggested that this vaccine was going to be a blockbuster. But the U.S. still hasn’t ordered extra doses at this point?

sharon lafraniere

Right. And according to Scott Gottlieb, who is a member of Pfizer’s board and the former commissioner of the Food and Drug Administration, Pfizer was still offering— after the results came out— more doses, but the U.S. did not seal a deal then.

michael barbaro

Hm. So the Trump administration, the U.S. government, having missed this first chance back in July to lock in this deal for extra doses of this vaccine at no cost, is then told in October, and it sounds like even in November, we can’t offer you the exact same timeline. I mean, because months have gone by here. We’ve gotten other orders. And so as a result, despite how promising this vaccine turns out to be, the U.S. still decides not to order more. I just want to be clear.

sharon lafraniere

That seems to be the situation, yes. And then on November 11, which is basically two days after Pfizer has announced these amazing results, it announces that it has a deal to sell 200 million doses to the European Union. That was a contract that had been in negotiation for weeks and weeks. Nonetheless, the European Union has locked in 200 million doses, and the U.S. has locked in a hundred million doses.

michael barbaro

So it very much looks like the European Union got 200 million doses of the vaccine that could have gone to the United States if the United States had wanted them.

sharon lafraniere

Yes, that’s what it looks like.

michael barbaro

Sharon, do we know who exactly in the U.S. government made this decision repeatedly not to buy these vaccines?

sharon lafraniere

We’re not sure. We know that Pfizer was dealing with the guy who is the scientific leader of Operation Warp Speed. His name is Dr. Moncef Slaoui. But whether Dr. Slaoui was the one who was the final decision-maker or it was Alex Azar, the Health and Human Services secretary, or whether the White House was involved or not, we really don’t know now.

michael barbaro

So Sharon, if you could summarize it, what are the consequences of how the U.S. has approached these offers from Pfizer?

sharon lafraniere

So the consequence is that the U.S. might have to wait longer for as much supply of the Pfizer vaccine as it wants and needs. Because the state of play is that Pfizer is right on the brink of getting emergency approval from the Food and Drug Administration. It’s going to be the first vaccine to get that in the U.S. And the US government has locked in a commitment for a hundred million doses, enough to cover 50 million people, and it wants more. But it looks very unlikely that it can get it as soon as it wants it.

michael barbaro

So how much time have we lost here when it comes to the Pfizer vaccine orders that we never placed?

sharon lafraniere

So what we’re being told is that the U.S. government has now asked Pfizer for a hundred million doses, and they want them starting in March. But Pfizer is saying, sorry, we cannot guarantee you these doses until June. So if that’s how it all plays out, the way it’s looking now, then we would have lost three months.

michael barbaro

Three months. Three months of not having tens of millions of doses that the U.S. could have had.

sharon lafraniere

If it works out that way, that would be three months in which the U.S. is waiting for a Pfizer vaccine because it didn’t lock in more doses earlier.

[music]michael barbaro

We’ll be right back.

Sharon, having made this decision, which in retrospect feels like a pretty strange and bad decision, what does the United States now do to correct for this? Could we just beg Pfizer to make extra doses for us?

sharon lafraniere

No, because it’s not that Pfizer is not willing to make more doses for Americans. It’s making every dose that it can possibly make right now. It doesn’t have empty factories somewhere where it can go in and just flip on the lights and suddenly there’s lots more doses. It has legal commitments to other countries to provide supply. And those countries want it too. It’s not a matter of begging Pfizer to make more. If they had more to give the Americans, they would give it to them. Pfizer has a very big motivation to put the U.S. first, because Pfizer, number one, it’s an American company.

michael barbaro

Right.

sharon lafraniere

Number two, most of its customers are in the U.S. They do not want to be in this situation where their customers think, what, you’re making deals to save the lives of Europeans and you’re leaving Americans here waiting for lifesaving vaccines? They don’t want a consumer backlash.

michael barbaro

Could the U.S.— and here I’m just kind of exhausting American curiosity. Could the U.S. kind of forcefully take vaccine from Pfizer if it wanted to be extremely nationalistic and say, nobody gets doses outside the U.S. before we get doses?

sharon lafraniere

I mean, that seems highly unlikely that the U.S. government is going to move into Pfizer’s factories and rip up all its contracts and commandeer its doses. President Trump signed an executive order this week saying that Americans would get vaccine supplies first, but it seems pretty meaningless. It’s hard to imagine what the government could do to force Pfizer to redirect vaccine that it’s committed to other countries to Americans. I mean, some people have speculated, maybe could Pfizer team up with another pharmaceutical company like Merck? And then could there be some kind of partnership there that would allow it to increase production? But it cannot itself, now, just turn on a dime and create more production.

michael barbaro

OK, so with no great options for securing more doses from Pfizer right away, what can the U.S. do instead? How do we make up for those missing doses? I have to imagine the answer lies with these other companies that the U.S. has invested in.

sharon lafraniere

Exactly. Moderna is right behind Pfizer with a very similar vaccine that is proven to be equally effective. It’s likely to win emergency approval from the F.D.A. maybe a week after Pfizer does later this month. It too has committed to provide the U.S. with a hundred million doses. Like Pfizer, it has to deliver those doses by the end of the first quarter of next year. It’s easier to store than Pfizer’s, and it might be easier to ship. It’s a much smaller company than Pfizer, right? It spent 10 years without bringing a product successfully to market, but it’s done extremely well with this vaccine. So there’s the Moderna option.

michael barbaro

So if I’m keeping count correctly, 50 million Americans would be inoculated through Pfizer’s vaccine.

sharon lafraniere

Right.

michael barbaro

50 million Americans would be inoculated through Moderna’s vaccine. That still leaves a lot of Americans. So what about these other companies?

sharon lafraniere

So of the other four companies, two of them are sort of off the table right now because they haven’t even started their phase 3 clinical trials. Another one, AstraZeneca, which has developed its vaccine with University of Oxford researchers, is about halfway enrolled in its clinical trial here. And there are some questions about its data, its transparency. It’s had somewhat rocky relations with the F.D.A. And its early results have shown basically that for the full two-dose regime, it was shown to be about 62 percent effective. So you have to ask yourself, are Americans going to want to take a vaccine that’s 62 percent effective when they have two vaccines out there that are 95 percent effective?

michael barbaro

Right. And I think we all know the answer to that is probably no, not really. So it’s really kind of “Moderna and Pfizer or bust” for the moment.

sharon lafraniere

Well, there’s also Johnson & Johnson, and it expects to have clinical trial results early next year. But we don’t know if that vaccine worked or not. If it works, that gives us a third. But at the moment, the U.S. government has got, as you said, commitments for 200 million doses, which will cover a hundred million Americans. And the question is, what is going to happen at the end of March? Are we going to fall off some kind of vaccine cliff here? Or, is there going to be an interval in which people are not being vaccinated? Or, are there going to be enough doses to fill in the gap?

michael barbaro

Mhm. So what happens if we reach and go over a vaccine cliff?

sharon lafraniere

So the worst case scenario is that there is an interval in which Americans are waiting and that there’s some sort of break in the inoculation program. But we don’t know that’s true. We don’t know for sure that that’s going to happen. Moderna could fill in some of the gap. And at the moment, all we can say is that it kind of raises the anxiety level that we have two successful vaccines, and so far, we have not locked in enough doses to cover more than a hundred million Americans.

michael barbaro

Right. So no matter how you slice it, the chances of us going over a vaccine cliff, of suddenly having some period of some unknown duration where Americans are not being inoculated, which is not what we want, the chances of that are higher— correct me if I’m wrong— because the United States did not order more of these doses from Pfizer. Is that right?

sharon lafraniere

I think that’s right. The administration says that is not going to happen. We’re not going over this cliff. That there’s going to be enough vaccine for everybody, that there are more supplies coming in, that there are negotiations going all the time. That they feel confident that they are going to have enough vaccine doses for every single American who wants it by spring or the middle of next year.

michael barbaro

Mhm. But the government can’t assure that.

sharon lafraniere

Not yet.

michael barbaro

Sharon, it feels like the consequence of what the U.S. government, of what the Trump administration has done here, is time. You said that the decision-making here may have delayed this acquisition of vaccines by something like three months. Time is a very precious resource in this pandemic. Time is how we measure the number of people who get exposed to this virus, who get infected by it, who get killed by it. And so every single day matters. And so three months, 90 days, that really matters, right? It means more people are likely to get this virus and potentially to die from it.

sharon lafraniere

I mean, I really, really hope that’s not so. Well, the whole story is such a roller coaster, right? We get these amazing results from Pfizer and Moderna, and everybody is just ecstatic. And then we learn, whoa, we don’t have enough. And are we going to get enough? And everybody would feel much more comfortable if we had all these doses in the bank.

michael barbaro

Mhm. I mean, what makes this feel especially confounding is that vaccines have been the U.S. government’s approach to this pandemic, right? I mean, the Trump administration has not issued national lockdowns. It has not issued a national mask mandate. What it has said is that what will get us out of this pandemic is a vaccine. We are going all in on vaccines. It’s pretty much our only solution to the pandemic. So to have not done everything conceivably possible to get as many doses of the vaccine as we could, knowing that this is our solution, just becomes extremely hard to understand or explain.

sharon lafraniere

So in hindsight, some administration officials will say privately they wish that they had locked in more doses earlier. That this has exposed a kind of flaw in their strategy. And that now they’re scrambling to figure out how can they compensate for it. And that is weighing heavily on them.

michael barbaro

Sharon, thank you very much. We appreciate it.

sharon lafraniere

Thank you, Michael.

[music]michael barbaro

On Wednesday afternoon, Canada became the latest country to approve Pfizer’s vaccine, meaning that its citizens may start to receive it beginning next week. A few hours later, The Times reported that the United States had passed a grim new milestone on Wednesday— 3,000 deaths from the coronavirus in a single day. We’ll be right back.

[music]

Here’s what else you need to know today:

archived recording

No company should have this much unchecked power over our personal information and our social interactions.

michael barbaro

In a lawsuit filed on Wednesday, the Federal Trade Commission and attorneys general from 48 states called for breaking up Facebook.

archived recording

And that’s why we are taking action today and standing up for the millions of consumers and many small businesses that have been harmed by Facebook’s illegal behavior.

michael barbaro

The lawsuit accused the company of purchasing its rivals, including Instagram and WhatsApp, in order to eliminate potential competition and in the process, acting as an unlawful monopoly. In response, Facebook said that it would vigorously defend itself during what is expected to be a long and expensive legal battle.

[music]

That’s it for The Daily. I’m Michael Barbaro. See you tomorrow.